Kerstin M Ivarsson1, Shahriar Akaberi2, Elin Isaksson3, Eva Reihnér4, Rebecca Rylance5, Karl-Göran Prütz6, Naomi Clyne2, Martin Almquist7. 1. Department of Nephrology, Clinical Sciences Lund, Skåne, Sweden. 2. Department of Nephrology and Transplantation, Skane University Hospital Lund, Skåne, Sweden. 3. VO Urology, Division 4, Malmö, Sweden. 4. Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden. 5. National Registry Centre, Skane University Hospital Lund, Skåne, Sweden. 6. Department of Internal Medicine, Helsingborg Hospital, Helsingborg, Sweden. 7. Department of Surgery Section of Endocrine and Sarcoma, Skane University Hospital, Lund, Skåne, Sweden.
Abstract
BACKGROUND: Secondary hyperparathyroidism is a common condition in patients with end-stage renal disease and is associated with osteoporosis and cardiovascular disease. Despite improved medical treatment, parathyroidectomy (PTX) is still necessary for many patients on renal replacement therapy. The aim of this study was to evaluate the effect of PTX on patient survival. METHODS: A nested index-referent study was performed within the Swedish Renal Registry (SRR). Patients on maintenance dialysis and transplantation at the time of PTX were analysed separately. The PTX patients in each of these strata were matched for age, sex and underlying renal diseases with up to five referent patients who had not undergone PTX. To calculate survival time and hazard ratios, indexes and referents were assigned the calendar date (d) of the PTX of the index patient. The risk of death after PTX was calculated using crude and adjusted Cox proportional hazards regressions. RESULTS: There were 20 056 patients in the SRR between 1991 and 2009. Of these, 579 (423 on dialysis and 156 with a renal transplant at d) incident patients with PTX were matched with 1234/892 non-PTX patients. The adjusted relative risk of death was a hazard ratio (HR) of 0.80 [95% confidence interval (CI) 0.65-0.99] for dialysis patients at d who had undergone PTX compared with matched patients who had not. Corresponding results for the patients with a renal allograft at d were an HR of 1.10 (95% CI 0.71-1.70). CONCLUSIONS: PTX was associated with improved survival in patients on maintenance dialysis but not in patients with renal allograft.
BACKGROUND: Secondary hyperparathyroidism is a common condition in patients with end-stage renal disease and is associated with osteoporosis and cardiovascular disease. Despite improved medical treatment, parathyroidectomy (PTX) is still necessary for many patients on renal replacement therapy. The aim of this study was to evaluate the effect of PTX on patient survival. METHODS: A nested index-referent study was performed within the Swedish Renal Registry (SRR). Patients on maintenance dialysis and transplantation at the time of PTX were analysed separately. The PTXpatients in each of these strata were matched for age, sex and underlying renal diseases with up to five referent patients who had not undergone PTX. To calculate survival time and hazard ratios, indexes and referents were assigned the calendar date (d) of the PTX of the index patient. The risk of death after PTX was calculated using crude and adjusted Cox proportional hazards regressions. RESULTS: There were 20 056 patients in the SRR between 1991 and 2009. Of these, 579 (423 on dialysis and 156 with a renal transplant at d) incident patients with PTX were matched with 1234/892 non-PTXpatients. The adjusted relative risk of death was a hazard ratio (HR) of 0.80 [95% confidence interval (CI) 0.65-0.99] for dialysis patients at d who had undergone PTX compared with matched patients who had not. Corresponding results for the patients with a renal allograft at d were an HR of 1.10 (95% CI 0.71-1.70). CONCLUSIONS:PTX was associated with improved survival in patients on maintenance dialysis but not in patients with renal allograft.
Authors: John Cunningham; Stuart M Sprague; Jorge Cannata-Andia; Maria Coco; Martine Cohen-Solal; Lorraine Fitzpatrick; David Goltzmann; Marie-Helene Lafage-Proust; Mary Leonard; Susan Ott; Mariano Rodriguez; Catherine Stehman-Breen; Paula Stern; Jose Weisinger Journal: Am J Kidney Dis Date: 2004-03 Impact factor: 8.860
Authors: Santhi K Ganesh; Austin G Stack; Nathan W Levin; Tempie Hulbert-Shearon; Friedrich K Port Journal: J Am Soc Nephrol Date: 2001-10 Impact factor: 10.121
Authors: A M Alem; D J Sherrard; D L Gillen; N S Weiss; S A Beresford; S R Heckbert; C Wong; C Stehman-Breen Journal: Kidney Int Date: 2000-07 Impact factor: 10.612
Authors: Bryan Kestenbaum; Stephen L Seliger; Daniel L Gillen; Haimanot Wasse; Bessie Young; Donald J Sherrard; Noel S Weiss; Catherine O Stehman-Breen Journal: Kidney Int Date: 2004-01 Impact factor: 10.612
Authors: Rosa Jofré; Juan Manuel López Gómez; Javier Menárguez; José Ramón Polo; Martin Guinsburg; Teresa Villaverde; Isabel Pérez Flores; Diana Carretero; Patrocinio Rodríguez Benitez; Rafael Pérez García Journal: Kidney Int Suppl Date: 2003-06 Impact factor: 10.545
Authors: Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow Journal: J Am Soc Nephrol Date: 2004-08 Impact factor: 10.121